4,680 research outputs found
FIGURE 1. Coulteria a-c in Coulteria lewisiae (Leguminosae: Caesalpinioideae) a new species for Infiernillo region, Mexico
No full textFIGURE 1. Coulteria a-c pollen grains different views (J.L. Contreras 3048); d male flower style; e male flower stigma close up (J.L. Contreras 2510); f female flower stigma; g female flower abaxial sepal (JL. Contreras 3155).Published as part of Sotuyo, Solange & Contreras-Jiménez, José Luis, 2021, Coulteria lewisiae (Leguminosae: Caesalpinioideae) a new species for Infiernillo region, Mexico, pp. 220-226 in Phytotaxa 498 (3) on page 221, DOI: 10.11646/phytotaxa.498.3.8, http://zenodo.org/record/542428
Effects of dung-pad conditions and density on coprophagous beetle assemblages in a Mediterranean rangeland
No full textDung beetles highly depend on the ephemeral microhabitat dung which is food
resource and larval habitat at the same time. Environmental conditions surrounding a dung
pad, such as vegetation structure, have an impact on dung beetle assemblages. We
investigated the influence of dung conditions and surrounding habitat characteristics on
Mediterranean dung beetle assemblages in a permanently grazed landscape in northern
Sardinia. We sampled the dung beetle assemblages of donkey and horse dung in three
different vegetation types and assessed species richness and abundance of dung beetles.
Species richness was determined by dung and surrounding habitat conditions, whereas
abundance was solely affected by dung conditions. However, species richness and abundance
decreased with increasing dung density. The effect of dung density on species
richness varied depending on vegetation type, with dry grassland exhibiting the highest
number of dung beetles species at high dung density. Species composition in dung pads
was influenced by abiotic factors with dwellers being negatively affected by increasing
dung-pad temperature. Our results underline the importance of diverse vegetation, particularly with respect to the complexity of vegetation which interrelates with the
microclimate. Furthermore, our findings illustrate the negative effect of high dung densities
on dung beetle assemblages, suggesting that the degree of the intensity of use by grazing
animals is important when considering measures for the conservation of dung beetles
Reflections of a Jewish, Lesbian Author
No full textIn this essay, Jewish lesbian author Leslea Newman speaks of the importance of finding one's own identity reflected in works of literature, citing examples of her own work, and recommending the writings of other Jewish lesbian authors of merit
Identical rearranged forms of JC polyomavirus transcriptional control region in plasma and cerebrospinal fluid of acquired immunodeficiency syndrome patients with progressive multifocal leukoencephalopathy
No full textProgressive multifocal leukoencephalopathy (PML) is a fatal demyelinating disease of the central nervous system (CNS) caused by the human polyomavirus JC (JCV). JCV has a hypervariable noncoding transcriptional control region (TCR) that spans the origin of replication of the JCV genome through to the first ATG start codon for late gene transcription. The archetype form of TCR is frequently found in the urine and kidneys of healthy and immunocompromised subjects. However the rearranged forms, whose prototype is Mad-1, possibly generated by deletion and duplication of segments of the archetype sequence, are found in the brain and cerebrospinal fluid (CSF) of PML patients. In this study the authors compared JCV TCR detected in paired CSF, plasma, and urine samples of 11 acquired immunodeficiency syndrome (AIDS) patients affected by PML to try to determine where the rearranged JCV TCRs are selected. In one patient, it was also possible to amplify and sequence the TCR in the brain and lymphocytes. Moreover, in 5/11 patients, the CSF, plasma, and urine samples corresponding to 2 months after PML development were available; and in another patient, it was possible to sequence the TCR in plasma and lymphocytes sampled 8 months before the onset of PML. The presence of the same TCR sequences in all the CSF and plasma samples taken from individual patients could strengthen the hypothesis that the blood is a compartment where JCV may replicate and undergo rearrangement of the TCR. This further supports the hypothesis that JCV reaches the brain by a hematogenous route and indicates that the JCV TCR sequences detected in plasma could be used as an early marker of JCV pathogenicity before the clinical appearance of PML in immunocompromised patients
Injunctive Relief in the EU – Intellectual Property and Competition Law at the Remedies Stage
No full textIn dealing with applications for injunctive relief by the holders of FRAND-encumbered SEPs in the course of protracted licensing negotiations, any legal system faces the challenge of reaching the proper balance between predictability for stakeholders and differentiation between possible scenarios (tough negotiations, holdup, holdout or exclusion). In the EU, that challenge fell to be addressed first under the various national laws concerning remedies for intellectual property violations, as partially harmonized by Directive 2004/48. The outcome was not optimal. After German courts introduced competition law in the equation in Orange Book, the European Commission felt compelled to intervene with a different approach in Motorola and Samsung, leading to a reference to the CJEU in Huawei v ZTE. That ruling sets out an elaborate choreography that SEP holder and implementer must respect, in order to avoid breaching Article 102 TFEU or avert injunctive relief, respectively. Huawei represents a satisfactory compromise in practice, but its theoretical foundation in competition law is not solid. Subsequent case-law has unmoored Huawei from competition law and is turning it into a stand-alone lex specialis for injunctions in FRAND cases. In the longer run, legislative intervention might be preferable to de facto harmonization via competition law
Staging the life-world: Habermas and the recuperation of Austin speech act theory
No full textPT: J; CR: APEL KO, 1976, SPRACHPRAGMATIK PHIL AUSTIN JL, 1962, HOW TO DO THINGS WOR AUSTIN JL, 1970, PHILOS PAPERS CULLER J, 1982, DECONSTRUCTION DERRIDA J, 1977, GLYPH, V1 ECO U, 1992, UNDERSTANDING ORIGIN, P273 FISH S, 1987, TRACING LIT THEORY HABERMAS J, 1984, THEORY COMMUNICATIVE, V1 HABERMAS J, 1987, THEORY COMMUNICATIVE, V2 HABERMAS J, 1989, JURGEN HABERMAS SOC MARTINET A, 1962, FUNCTIONAL VIEW LANG, P24 QUINE WV, 1960, WORD OBJECT SEARLE JR, 1969, SPEECH ACTS SEARLE JR, 1977, GLYPH, V1 VANEEMEREN F, 1983, SPEECH ACTS ARGUMENT WARNOCK GJ, 1989, FL AUSTIN; NR: 16; TC: 0; J9: J THEOR SOC BEHAV; PG: 12; GA: KR147Source type: Electronic(1
MODEIN2 and Colby: computer codes for sediment transport computations
No full textNovember, 1976.CER76-77VMP-JL-DBS19
Genetically modified CD34+ cells as cellular vehicles for gene delivery into areas of angiogenesis in a rhesus model
No full textTo develop a cellular vehicle able to reach systemically disseminated areas of angiogenesis, we sought to exploit the natural tropism of circulating endothelial progenitor cells (EPCs). Primate CD34+ EPCs were genetically modified with high efficiency and minimal toxicity using a non-replicative herpes virus vector. These EPCs localized in a skin autograft model of angiogenesis in rhesus monkeys, and sustained the expression of a reporter gene for several weeks while circulating in the blood. In animals infused with autologous CD34+ EPCs transduced with a thymidine kinase-encoding herpes virus, skin autografts and subcutaneous Matrigel pellets impregnated with vascular growth factors underwent necrosis or accelerated regression after administration of ganciclovir. Importantly, the whole intervention was perfectly well tolerated. The accessibility, easy manipulation, lack of immunogenicity of the autologous CD34+ cell vehicles, and tropism for areas of angiogenesis render autologous CD34+ circulating endothelial progenitors as ideal candidates for exploration of their use as cellular vehicles when systemic gene delivery to those areas is required
Risk management and regulations for lower limb medical exoskeletons: a review
No full textYongtian He, David Eguren, Trieu Phat Luu, Jose L Contreras-Vidal Laboratory for Noninvasive Brain-Machine Interface Systems, Department of Electrical and Computer Engineering, University of Houston, Houston, TX, USA Abstract: Gait disability is a major health care problem worldwide. Powered exoskeletons have recently emerged as devices that can enable users with gait disabilities to ambulate in an upright posture, and potentially bring other clinical benefits. In 2014, the US Food and Drug Administration approved marketing of the ReWalk™ Personal Exoskeleton as a class II medical device with special controls. Since then, Indego™ and Ekso™ have also received regulatory approval. With similar trends worldwide, this industry is likely to grow rapidly. On the other hand, the regulatory science of powered exoskeletons is still developing. The type and extent of probable risks of these devices are yet to be understood, and industry standards are yet to be developed. To address this gap, Manufacturer and User Facility Device Experience, Clinicaltrials.gov, and PubMed databases were searched for reports of adverse events and inclusion and exclusion criteria involving the use of lower limb powered exoskeletons. Current inclusion and exclusion criteria, which can determine probable risks, were found to be diverse. Reported adverse events and identified risks of current devices are also wide-ranging. In light of these findings, current regulations, standards, and regulatory procedures for medical device applications in the USA, Europe, and Japan were also compared. There is a need to raise awareness of probable risks associated with the use of powered exoskeletons and to develop adequate countermeasures, standards, and regulations for these human–machine systems. With appropriate risk mitigation strategies, adequate standards, comprehensive reporting of adverse events, and regulatory oversight, powered exoskeletons may one day allow individuals with gait disabilities to safely and independently ambulate. Keywords: FDA, ReWalk, Indego, Ekso, HAL, Re
Tunneling microscopy of NbSe2 in air
No full textPT: J; CR: BANDO H, 1987, JPN J APPL PHYS PT 2, V26, L41 BINNIG G, 1982, PHYS REV LETT, V49, P57 BRYANT A, 1986, APPL PHYS LETT, V48, P832 FELDMAN JL, 1976, J PHYS CHEM SOLIDS, V37, P1141 FELDMAN JL, 1981, J PHYS CHEM SOLIDS, V42, P1029 JERICHO MH, 1980, PHYS REV B, V22, P4907 JERICHO MH, 1987, REV SCI INSTRUM, V58, P1349 MAMIN HJ, 1986, PHYS REV B, V34, P9015 PETHICA JB, 1986, IBM J RES DEV, V30, P455 RAO GVS, 1979, PHYSICS CHEM MATERIA, P99 SOLER JM, 1986, PHYS REV LETT, V57, P444 TERSOFF J, 1986, PHYS REV LETT, V57, P440 TOKUMOTO H, 1986, JPN J APPL PHYS, V25, L621; NR: 13; TC: 14; J9: J APPL PHYS; PG: 4; GA: L5219Source type: Electronic(1
- …
